Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9416529 | 0.84 | SLC2A4 (0.75) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL160617 | 0.80 | CYP3A4 (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL29594115 | 0.80 | CYP3A4 (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL13939472 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL6254596 | 0.80 | SLC2A4 (0.65) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL1488012 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| SCHEMBL1488015 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL473713 | 0.78 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298981 | 0.78 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 | |
| 3-Hydroxybenzylhydrazine Dihydrochloride SCHEMBL31298984 | 0.78 | MAPT (1.00) | CYP3A4CYP1A2PKMALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110729-A1 | Primary N-hydroxylamines | NIH | 2004-06-10 | — | — | US | claimed |
| US-6455589-B1 | AN ORALLY ADMINISTRABLE EFFECTIVE UNIT SOLID DOSAGE OF A PRIMARY N-HYDROXYLAMINE OR A SALT, FREE OF NITRONE; USEFUL FOR REDUCING OXIDATIVE DAMAGE OR DELAYING SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-24 | — | — | US | claimed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | CYP3A4 4792/4885CYP1A2 3841/4885PKM 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.